Exploring the relationship between gut microbiome and cachexia in chronic kidney disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the links between cachexia and the gut microbiome in patients with chronic kidney disease (CKD) undergoing dialysis. It will establish a prospective cohort of patients receiving various forms of dialysis, including hemodialysis and peritoneal dialysis. Researchers will collect clinical data, biological samples, and assess body composition, inflammatory markers, and uremic toxins over time to better understand the role of the gut microbiome in CKD cachexia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of kidney failure (stage V)
* Maintenance dialysis for at least 3 months
* Understanding of the trial procedures and ability to adhere to the trial protocol

Exclusion Criteria:

* Severe nonadherence to the dialysis procedure
* Life expectancy below 1 year
* Chronic inflammatory disease of the digestive tract (Crohn's disease, ulcerative colitis)
* Bariatric surgery
* Active cancer
* Pregnancy
* Antibiotics consumption in the month preceding the inclusion
* Gastro-intestinal surgery, colonoscopy, or probiotics consumption in the 3 months preceding the inclusion
* Drugs influencing body composition initiated ≤ 1 month : systemic corticosteroids, anabolic drugs as insulin or testosterone, post-menopausal hormone therapy, injectable contraceptives.
* Known endocrinological disorders potentially leading to hypo- or hypermetabolism, untreated or treated for ≤ 1 month : disorders of thyroid gland, adrenal glands...
* Patients under weight loss drugs : GLP1 agonists, orlistat

Where it's running

• Cliniques universitaires Saint-Luc
  Brussels, Belgium Recruiting
• UCLouvain
  Brussels, Belgium Not yet recruiting

Study contacts

• Principal investigator: Inès Dufour, MD — Université Catholique de Louvain
• Study coordinator: Laure Bindels, PhD
• Email: laure.bindels@uclouvain.be
• Phone: +32(2)7647337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS010 in advanced cancer with cachexia: safety and early signals in adults

  This study tests DS010 in adults with cancer and cachexia to see if it is safe and whether it might help with their condition.

  Recruiting at 4 sites Phase 1/2 Dartsbio Pharmaceuticals Ltd. · Concord West, New South Wales and 3 other locations · NCT07921576

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Spatial multi-omics and AI-based early warning for pancreatic cancer cachexia

  This study tests whether spatial multi-omics data can reveal how the tumor and body metabolism interact in pancreatic cancer cachexia and whether a multimodal AI model can predict cachexia early in adults with pancreatic ductal adenocarcinoma.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07670286

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics

  This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.

  Recruiting China Medical University, China · Shenyang, Liaoning · NCT07519837

• GB18 injection for tumor cachexia in cancer patients

  This study tests GB18, a humanized GDF15 antibody, to see if it helps cancer patients with cachexia when given as subcutaneous injections.

  Recruiting at 2 sites Phase 1 Kexing Biopharm Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07519564

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.